AZD3293
AZD3293, also known by its developmental code names LY3314814 or Lanabecestat, is an experimental drug that was being investigated for its potential use in the treatment of Alzheimer's disease. AZD3293 is an orally active small molecule that functions as a beta-secretase inhibitor. By inhibiting the activity of beta-secretase, AZD3293 aims to reduce the production of amyloid-beta peptides, which are thought to play a critical role in the pathogenesis of Alzheimer's disease by forming amyloid plaques in the brain.
Mechanism of Action[edit | edit source]
AZD3293 works by targeting and inhibiting the beta-secretase enzyme, also known as BACE1. BACE1 is involved in the cleavage of the amyloid precursor protein (APP) to produce amyloid-beta peptides. The accumulation of these peptides leads to the formation of amyloid plaques, a hallmark of Alzheimer's disease. By inhibiting BACE1, AZD3293 reduces the production of amyloid-beta peptides, potentially slowing the progression of Alzheimer's disease.
Clinical Trials[edit | edit source]
Clinical trials for AZD3293 have been conducted to evaluate its safety, tolerability, and efficacy in patients with Alzheimer's disease. The drug has progressed through various phases of clinical trials, including Phase I and Phase II studies that assessed its pharmacokinetics, pharmacodynamics, and preliminary efficacy. However, in June 2018, it was announced that the Phase III clinical trials of AZD3293 were being discontinued due to the lack of efficacy, marking a significant setback in its development.
Potential Impact and Challenges[edit | edit source]
The development of AZD3293 had generated significant interest due to the urgent need for effective treatments for Alzheimer's disease. Despite the discontinuation of its clinical trials, the research on AZD3293 contributes to the broader understanding of Alzheimer's disease and the role of amyloid-beta in its pathogenesis. The challenges faced in the development of AZD3293 highlight the complexities of targeting amyloid-beta in Alzheimer's disease and underscore the need for continued research in this area.
See Also[edit | edit source]
References[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
